natgillin/translations-raw huggingface dataset:
However, these adverse reactions (abdominal pain, diarrhoea, nausea and fatigue) are mild or moderate, transient, of short duration but may require dose adjustment or additional concomitant medicinal products, see section 4.2. Fatigue has been reported as very common.
Ti neželeni učinki (bolečine v trebuhu, driska, navzea in utrujenost) so blagi ali zmerni, prehodni in kratkotrajni, lahko pa zahtevajo prilagoditev odmerka ali dodatno sočasno zdravljenje z drugimi zdravili, glejte poglavje 4.2. Zelo pogosto so poročali o utrujenosti.
However, these events did not occur at a higher frequency with rivastigmine 13.3 mg/24 h transdermal patches than with placebo.
Vendar pa se ti dogodki niso pojavljali pogosteje pri uporabi transdermalnega obliža z rivastigminom 13,3 mg/24 h v primerjavi s placebom.
However, these patients should be carefully monitored and the dose of cholic acid titrated individually
Vendar je treba te bolnike skrbno spremljati, odmerek holne kisline pa titrirati individualno.
However, these transporters have minimal impact on dabrafenib oral bioavailability and elimination and the risk for clinically relevant drug-drug interactions with inhibitors of Pgp or BCRP is low.
Vendar ta prenašalca le minimalno vplivata na peroralno biološko uporabnost in odstranjevanje dabrafeniba in tveganje za klinično pomembno medsebojno delovanje zdravil z zaviralci Pgp ali BCRP je majhno.
However, these were not evident from clinical trials with Optimark.
Vendar pa teh reakcij v kliničnih preskušanjih zdravila Optimark ni bilo.
However, these withdrawal periods in cattle are only valid when Naxcel has been injected under the skin in non- edible tissue at the recommended location (the base of the ear).
Navedena obdobja karence pri govedu veljajo le, če je bilo zdravilo Naxcel injicirano pod kožo v neužitno tkivo na priporočenem mestu (pod ušesom).
However, they must be distinguished from haemolytic anaemia which commonly occurs where there is elevated serum free copper in uncontrolled Wilson’s disease.
Razlikovati pa jih moramo od hemolitične anemije, ki se pogosto pojavi, kadar je pri neobvladani Wilsonovi bolezni zvišan prosti baker v serumu.
However, this does not preclude the occurrence of hepatic events in patients with cirrhosis (including hepatocarcinoma).
omogoči klinično »ozdravitev« kronične okužbe z virusom hepatitisa C. To pa ne pomeni, da ne bo prišlo do jetrnih dogodkov pri bolnikih s cirozo (vključno s hepatokarcinomom).
However, this finding is not clinically relevant as systemic exposure for both elderly and young subjects remained very low from ocular dosing.
Vendar ti rezultati niso klinično pomembni, ker je sistemska izpostavljenost pri očesnem odmerjanju za obe starostni skupini bolnikov zelo nizka.
However, this has not formally been studied in patients with impaired renal or hepatic function; therefore patients with severe renal or hepatic impairment should be carefully monitored for any adverse effects.
Vendar pa formalnih študij pri bolnikih z okvarjenim delovanjem ledvic ali jeter niso izvedli; zato je treba bolnike z okvarjenim delovanjem ledvic ali jeter skrbno spremljati glede katerihkoli neželenih učinkov.
However, this may increase the risk of bleeding.
Toda ta učinek lahko poveča nevarnost krvavitve.
However, this medicine may cause dizziness (see section 4 “Possible side effects”).
Lahko pa to zdravilo povzroča omotičnost (glejte poglavje 4 “Možni neželeni učinki”).
However, this raises no safety concern regarding target or special populations as hepatic impairment is contraindicated and the phase III clinical studies included a considerable number of elderly patients and patients with mild to moderate renal impairment.
Vendar to ne pomeni nobenih varnostnih zadržkov glede ciljnih ali posebnih populacij, ker okvara jeter pomeni kontraindikacijo, klinične študije III. faze pa so vključile veliko starejših bolnikov in bolnikov z blago do zmerno okvaro ledvic.
However, this route of administration may result in suboptimal immune response to the vaccine (see section 4.4).
Vsekakor pa se lahko zaradi tega pričakuje pomanjkljiv imunski odgovor na cepljenje (glejte poglavje 4.4).
However, thoughts of harming others, physical assault or threatening behaviour were observed in some patients (< 1% in perampanel clinical studies).
Vendar pa so pri nekaterih bolnikih opazili razmišljanja o poškodovanju drugih, fizičnemu napadu ali grozečemu vedenju (< 1 % v kliničnih študijah s perampanelom).
However, Thyrogen has the advantage of allowing patients to remain on their replacement therapy before the test is carried out, resulting in a better quality of life, as the temporary withdrawal of the replacement therapy has transient side- effects which cannot always be tolerated easily.
Prednost zdravila Thyrogen pa je v tem, da bolnikom omogoča, da pred izvedbo testa še vedno prejemajo nadomestno zdravljenje, kar jim zagotavlja boljšo kakovost življenja, saj ima začasna prekinitev nadomestnega zdravljenja prehodne neželene učinke, ki jih bolniki včasih težko prenašajo.
However, TPMT also catalyses the S-methylation of the principle nucleotide metabolite, TIMP, to form methylthioinosine monophosphate (mTIMP).
Vendar pa TPMT katalizira tudi S-metilacijo glavnega presnovka nukleotida TIMP v metiltioinozin monofosfat (mTIMP).
However, Tracleer can induce hypotension (decrease of your blood pressure) which can make you feel dizzy, affect your vision and affect your ability to drive and use machines.
Zdravilo Tracleer lahko povzroči hipotenzijo (znižanje krvnega tlaka), zaradi česar ste lahko omotični ali poslabšanje vida, kar lahko vpliva na vašo sposobnost vožnje ali uporabe strojev.
However, Tracleer can induce hypotension (decrease of your blood pressure) which can make you feel dizzy, affect your vision and affect your ability to drive and use machines.
Zdravilo Tracleer lahko povzroči hipotenzijo (znižanje krvnega tlaka), zaradi česar ste lahko omotični, ali poslabšanje vida, kar lahko vpliva na vašo sposobnost vožnje ali uporabe strojev.
However, Tracleer may induce hypotension, with symptoms of dizziness, blurred vision or syncope that could affect the ability to drive or use machines.
Zdravilo Tracleer lahko povzroči hipotenzijo s simptomi omotice, zamegljenega vida ali sinkope, ki bi lahko vplivala na sposobnost vožnje in upravljanja s stroji.
However, trastuzumab may elevate the overall exposure of one doxorubicin metabolite, (7-deoxy-13 dihydro-doxorubicinone, D7D).
Trastuzumab pa lahko zviša celokupno izpostavljenost enemu metabolitu doksorubicina (7-deoksi-13- dihidro-doksorubicinonu, D7D).
However, two cases of arthralgia have been observed in children in clinical studies with Quinsair and long-term safety data are missing especially considering the effects on cartilage observed in animals. (See sections 4.2 and 5.3.)
Vendar pa so pri otrocih v kliničnih študijah z zdravilom Quinsair opazili dva primera artralgije, dolgoročni podatki o varnosti pa manjkajo, zlasti ob upoštevanju učinkov na hurstanec, ki so jih ugotovili pri živalih. (Glejte poglavji 4.2 in 5.3).
However, unless the patient has renal impairment, no dosage adjustment of lamivudine is necessary.
Če bolnik nima oslabljenega delovanja ledvic, odmerka lamivudina kljub temu ni treba prilagoditi.
However, upon co-administration with cobicistat in Genvoya, near maximal inhibition of P-gp by cobicistat is achieved leading to increased availability of tenofovir alafenamide with resulting exposures comparable to tenofovir alafenamide 25 mg administered alone.
Vendar pa sočasno dajanje kobicistata z zdravilom Genvoya povzroči, da kobicistat skoraj maksimalno zavira P-gp, kar povzroči povečano razpoložljivost alafenamidtenofovirata, zato je posledično izpostavljenost primerljiva z alafenamidtenofoviratom 25 mg, ko se ga daje samega.
However, use only injection syringes which are designed for an insulin concentration of 100 units per millilitre.
Uporabite le injekcijske brizge, ki so zasnovane za koncentracije insulina 100 enot na mililiter.
However, use only injection syringes which are designed for an insulin concentration of 100 Units per millilitre.
Vendar pa uporabite izključno brizge, namenjene injiciranju insulinov s koncentracijo 100 enot na mililiter.
However, use only injection syringes which are designed for an insulin concentration of 100 Units per millilitre.
Vendar pa uporabite izključno injekcijske brizge, namenjene injiciranju insulinov s koncentracijo 100 enot na mililiter.
However, Vantobra differs from Tobi by having a higher concentration of the active substance and is inhaled using a different type of nebuliser.
Zdravilo Vantobra se od zdravila Tobi razlikuje po tem, da ima višjo koncentracijo zdravilne učinkovine in da se inhalira z drugo vrsto nebulatorja.
However, vector insertions into chromosomal regions previously associated with leukaemia in comparable trials of gene therapy in Wiscott Aldrich Syndrome, X-SCID and Chronic Granulomatous Disease have been documented.
Vendar pa so bili v primerljivih preskušanjih genskega zdravljenja pri Wiscott-Aldrichevem sindromu, X-SCID in kronični granulomatozni bolezni dokumentirani primeri vstavitve vektorja v kromosomske regije, predhodno povezane z levkemijo.
However, Viread was shown to produce similar levels of the active substance in the body as in adults, and it was judged that the results were influenced by the type of patients included in the Viread group.
Vendar pa je bilo dokazano, da je zdravilo Viread doseglo podobno raven zdravilne učinkovine v telesu kot pri odraslih, pri čemer je bilo ocenjeno, da je na rezultate vplivala vrsta bolnikov, vključena v skupino, ki je prejemala zdravilo Viread.
However, weekly obinutuzumab dosing from post-coitum day 20 to delivery resulted in complete depletion of B cells in infant monkeys at weekly intravenous obinutuzumab doses of 25 and 50 mg/kg (2-5 times the clinical exposure based on Cmax and AUC).
Toda vsakotedenska uporaba od 20. postkoitalnega dne do poroda je pri opičjih mladičih povzročila popolno odsotnost celic B ob tedenskih intravenskih odmerkih obinutuzumaba od 25 do 50 mg/kg (to je od 2- do 5-kratnik klinične izpostavljenosti na podlagi Cmax in AUC).
However, when analysing the subset of patients aged 18 years and above alone, an average improvement of around 5.0 percentage points was seen in patients who took Kalydeco compared with patients who took placebo.
Vendar pa je bilo pri analizi samo podskupine bolnikov, starejših od 18 let, opaziti izboljšanje za 5,0 odstotne točke pri bolnikih, ki so jemali zdravilo Kalydeco, v primerjavi s tistimi, ki so jemali placebo.
However, when driving or using machines, it should be taken into account that dizziness and somnolence have been reported with sitagliptin.
Vendar pa je treba pri vožnji in upravljanju s stroji upoštevati, da so pri uporabi sitagliptina poročali o omotici in zaspanosti.
However, when driving or using machines, it should be taken into account that dizziness and somnolence have been reported.
Vendar pa je treba pri vožnji ali upravljanju s stroji upoštevati, da so poročali o omotici in zaspanosti.
However, when driving vehicles or operating machinery it must be borne in mind that dizziness or weariness may occasionally occur when taking Rasilez.
Vendar pa je pri vožnji in upravljanju s stroji treba upoštevati, da lahko med jemanjem zdravila Rasilez občasno pride do omotičnosti in preutrujenosti.
However, when driving vehicles or operating machinery it must be borne in mind that dizziness or weariness may occasionally occur when taking Riprazo.
Vendar pa je pri vožnji in upravljanju s stroji treba upoštevati, da lahko med jemanjem zdravila Riprazo občasno pride do omotičnosti in preutrujenosti.
However, when driving vehicles or operating machinery it must be borne in mind that dizziness or weariness may occasionally occur when taking Riprazo.
Vendar pa je pri vožnji in upravljanju s stroji treba upoštevati, da lahko med jemanjem zdravila Riprazo občasno pride do omotičnosti in preutrujenosti.Riprazo
However, when driving vehicles or using machines it should be taken into account that occasionally dizziness, asthenia or syncope may occur.
Vendar je pri vožnji ali upravljanju strojev treba upoštevati, da se lahko občasno pojavi omotičnost, astenija ali sinkopa.
However, when initiating lumacaftor/ivacaftor in patients taking strong CYP3A inhibitors, the dose should be reduced to one tablet daily (lumacaftor 200 mg/ivacaftor 125 mg total daily dose) for the first week of treatment to allow for the steady state induction effect of lumacaftor.
Kadar pa uvajamo lumakaftor/ivakaftor bolnikom, ki jemljejo močne zaviralce CYP3A, moramo prvi teden zdravljenja odmerek zmanjšati na eno tableto na dan (skupni dnevni odmerek lumakaftor 200 mg/ivakaftor 125 mg), s čimer upoštevamo spodbujevalni učinek lumakaftorja v stanju dinamičnega ravnovesja.
However, when initiating Orkambi in patients taking strong CYP3A inhibitors, the dose should be reduced to one tablet daily (lumacaftor 200 mg/ivacaftor 125 mg total daily dose) for the first week of treatment to allow for the steady state induction effect of lumacaftor.
Kadar pa uvajamo zdravilo Orkambi pri bolnikih, ki jemljejo močne zaviralce CYP3A, moramo prvi teden zdravljenja odmerek zmanjšati na eno tableto na dan (skupni dnevni odmerek lumakaftor 200 mg/ivakaftor 125 mg), s čimer upoštevamo indukcijski učinek lumakaftorja v stanju dinamičnega ravnovesja.
However, when initiating treatment with Victoza in combination with a sulfonylurea or a basal insulin, blood glucose self­monitoring may become necessary to adjust the dose of the sulfonylurea or the basal insulin.
Vendar bodo bolniki na začetku zdravljenja z zdravilom Victoza v kombinaciji s sulfonilsečnino ali z bazalnim insulinom morda morali izvajati samokontrolo glukoze v krvi, da bo mogoče prilagoditi odmerek sulfonilsečnine ali bazalnega insulina.
However, when looking at the 381 patients who had particularly high levels of iron in their liver at the beginning of the study and who received comparable amounts of Exjade and deferoxamine, the two medicines were as effective as each other.
Vendar pa sta bili pri 381 bolnikih, ki so imeli posebno visoke ravni železa v jetrih na začetku študije in so prejemali primerljive količine zdravila Exjade in deferoksamina, obe zdravili enako učinkoviti.
However, when Tasmar therapy is being discontinued for reasons other than too much levodopa, levodopa dosemay have to be increased to levels equal to or greater than before initiation of Tasmar therapy, especially if the patient had large decreases in levodopa when starting Tasmar.
Kadar pa terapijo z zdravilom Tasmar prekinemo zaradi razlogov, drugačnih kot je presežek levodope, bo odmerek levodope verjetno treba zvečati na enak ali večji kot pred uvedbo terapije z zdravilom Tasmar, še posebno, če so bolniku odmerek levodope po uvedbi zdravila Tasmar močno zmanjšali.
However, when used in combination with a sulphonylurea or a basal insulin, blood glucose monitoring or blood glucose self- monitoring may become necessary to adjust the doses of the sulphonylurea or the basal insulin.
Toda pri uporabi zdravila Lyxumia v kombinaciji s sulfonilsečnino ali bazalnim insulinom je lahko kontrola ali samokontrola glukoze v krvi potrebna za prilagoditev odmerkov sulfonilsečnine ali bazalnega insulina.
However, you and your doctor may decide that you may inject Stelara yourself.
Z zdravnikom se lahko dogovorite, da si boste zdravilo Stelara injicirali sami.
However, you may find that VIAGRA takes longer to start working if you take it with a heavy meal.
Čeprav boste morda ugotovili, da v primeru zaužitja zdravila s težjim obrokom, lahko traja dlje, preden zdravilo VIAGRA začne delovati.
However, you may find that Vizarsin takes longer to start working if you take it with a heavy meal.
Morda boste ugotovili, da zdravilo začne delovati kasneje, če ga zaužijete s težjim obrokom.
However, you should check that the patch has not fallen off after doing these activities.
Kljub temu priporočamo, da po njih preverite, ali je obliž še vedno na svojem mestu.
However, you should check with your doctor whether drinking alcohol is advisable for you.
O primernosti pitja alkohola se posvetujte s svojim zdravnikom.
However, you should check with your doctor whether drinking alcohol is advisable for you.
Vendar se z zdravnikom posvetujte, ali je priporočljivo, da pijete alkohol.
However, you should contact your doctor, nurse or pharmacist if this does happen.
A če se to zgodi, se kljub temu posvetujte z zdravnikom, medicinsko sestro ali farmacevtom.
However, you should not dilute with other liquids or mix with other food prior to taking ABILIFY oral solution.
Vendar pa peroralne raztopine ABILIFY pred zaužitjem ne smete redčiti z drugimi tekočinami ali mešati s hrano.
However, you should seek immediate treatment in any event. serum sickness like disease (a hypersensitivity reaction to the administration of a foreign serum with symptoms like fever, swelling, skin rash, enlargement of the lymph nodes)
V vsakem primeru morate nemudoma poiskati zdravniško pomoč. serumski bolezni podobno stanje (preobčutljivostna reakcija po dajanju tujega seruma s simptomi, kot so zvišana telesna temperatura, otekline, kožni izpuščaj, povečanje bezgavk).
However, your ability to drive and use machines may be affected by side effects such as fatigue (if present).
Vendar lahko na sposobnost upravljanja vozil in strojev vplivajo neželeni učinki, kot je utrujenost (če je prisotna).
However, your doctor may give you a further dose of 0.5 to 1 mg per kg of body weight, if necessary.
Po potrebi vam bo zdravnik dal dodaten odmerek med 0,5 in 1 mg na kilogram telesne mase.
However, your doctor may recommend a lower dose of 20 mg or a higher dose of 80 mg.
Vaš zdravnik vam je predpisal eno 40 mg tableto dnevno.
However, your dose may have to be increased even further.
Včasih je treba odmerek še povečati.
However, your dose may have to be increased even further.
Če imate dodatna vprašanja, se posvetujte z zdravnikom ali s farmacevtom.
However, Zinbryta’s effect on other vaccines (live vaccines) is not known.
Vendar pa učinek zdravila Zinbryta na druga cepiva (živa cepiva) ni znan.
However, ZOSTAVAX is expected to have no or negligible influence on ability to drive and use machines.
Vendar se pri cepivu ZOSTAVAX pričakuje, da nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
However,a causal relationship has not been established.
Vzročna povezanost ni dokazana.
hown to cause profound decreases in
bilo, da povzročata precejšnje zmanjšanje
hown to significantly increase
atazanavir/ritonavir močno
hows the number of doses left shows whether the nasal spray is locked or ready for use
število preostalih odmerkov ali je pršilo za nos zaklenjeno ali pripravljeno za uporabo
HPDE bottles carton and HPDE bottles of 60 tablets
Škatla za steklenice iz HPDE in steklenice iz HPDE, ki vsebujejo 60 tablet
HPDE bottles carton and HPDE bottles of 90 tablets
Škatla za steklenice iz HPDE in steklenice iz HPDE, ki vsebujejo 90 tablet
HPV 16- or
CIN 2/3 ali
HPV 16- or 18-related CIN 2/3 or AIS**
CIN 2/3 ali AIS, povezane s HPV 16 ali 18
HPV 16/18-
AIS,
HPV 16/18-
AIS, povezana s
HPV 16/18-
CIN 2/3 ali
HPV 16/18-
CIN 3,
HPV 16/18- related CIN 2/3 or AIS
CIN 2/3 ali
HPV 18- related CIN
povezana s
HPV 18- related CIN 2/3 or AIS
CIN 2/3 ali
HPV 31-, 33-, 45-, 52-, 58-related
CIN3, povezane s HPV 31, 33, 45, 52 in
HPV 31-, 33-, 45-, 52-, 58-related cervical definitive therapy procedures†
Definitivni terapevtski posegi na materničnem vratu†, povezani s HPV 31, 33, 45, 52 in 58
HPV 31-, 33-, 45-, 52-, 58-related cervical definitive therapy procedures†
Persistentna okužba, ≥ 6 mesecev§, povezana s HPV 31, 33, 45, 52 in 58
HPV 31-, 33-, 45-, 52-, 58-related CIN 2/3 or AISα
ASC-US pozitivne na HPV-HR, povezane s HPV 31, 33, 45, 52 ali 58 ali hujši nenormalni Pap#
HPV 31-, 33-, 45-, 52-, 58-related CIN 2/3 or AISα
CIN 2/3 ali AIS, povezane s HPV 31, 33,
HPV 31-, 33-, 45-, 52-, 58-related CIN 2/3,
Persistentna okužba ≥ 12 mesecev¶, povezana s HPV 31, 33, 45, 52 in 58
HPV 31-, 33-, 45-, 52-, 58-related VIN 2/3, VaIN 2/3
Definitivni terapevtski posegi na materničnem vratu†, povezani s HPV 31, 33, 45, 52 in 58
HPV 6-, 11-, 16- or 18-related VaIN 2/3
VaIN 2/3, povezane s HPV 6, 11, 16 ali 18
HPV 6-, 11-, 16- or 18-related VIN 2/3
VIN 2/3, povezane s HPV 6, 11, 16 ali 18
HPV 6-, 11-, 16-, 18-related VaIN 2/3 was 85.7% (95% CI: 37.6, 98.4), and against HPV 6-, 11-, 16-,
HPV 18 povezanim VaIN 2/3 85,7 % (95-odstotni IZ: 37,6; 98,4), proti s HPV 6, HPV 11, HPV 16 ali
HPV 6-, 11-, 16-, or 18-related Genital Warts***
Genitalne bradavice, povezane s HPV 6, 11, 16 ali 18
HPV 6-, 11-, 16-, or 18-related PIN 1/2/3***
PIN 1/2/3, povezane s HPV 6, 11, 16 ali 18
HPV 6/11/16/18-related external genital lesions
s HPV 6/11/16/18 povezane lezije na zunanjih spolovilih
HPV Type 11 and 18 L1 protein 40 µg
L1 protein HPV tipa 11 in 18 40 µg
HPV Type 16 L1 protein 60 µg HPV Type 31, 33, 45, 52 and 58 L1 protein 20 µg
L1 protein HPV tipa 16 60 µg L1 protein HPV tipa 31, 33, 45, 52 in 58 20 µg
HPV type 16 L1 protein1,2 20 micrograms
L1 protein genotipa 16 HPV1,2 20 mikrogramov
HPV type 18 L1 protein1,2 20 micrograms
L1 protein genotipa 18 HPV1,2 20 mikrogramov
HPV Type 6 L1 protein 30 µg
L1 protein HPV tipa 6 30 µg
HPV- 16/18 endpoint
Opazovani dogodek HPV-16/18
HPV- 16/18 endpoint
Opazovani dogodek v zvezi s HPV-16/18
HPV-16 related types (A9 species)
S HPV-16 povezani tipi (vrsta A9)
HPV-16 related types (A9 species)
s HPV-16 sorodni tipi (vrste A9)
HPV-16/18 endpoint
Opazovani dogodek HPV-16/18
HPV-18 related types (A7 species)
S HPV-18 povezani tipi (vrsta A7)
HPV-18 related types (A7 species)
s HPV-18 sorodni tipi (vrste A7)
HPV-31, 33 and 45 showed consistent cross-protection for 6-month persistent infection and CIN2+ endpoints in all study cohorts.
HPV-31, 33 in 45 so pokazali dosledno navzkrižno zaščito pri naslednjih opazovanih dogodkih: 6- mesečna persistentna okužba in CIN2+ v vseh študijskih kohortah.
HPV-31, 33 and 45 showed consistent cross-protection for 6-month persistent infection and CIN2+ endpoints in all study cohorts.
HPV-31, 33 in 45 so pokazali dosledno navzkrižno zaščito pri naslednjih opazovanih dogodkih: 6- mesečna persistentna okužba in CIN2+v vseh študijskih kohortah.
HR
HR RO
HR
SI
HR (95 % CI)
Razmerje ogroženosti (95-% IZ)
HR (95 % CI)
ROg (95 % IZ)
HR (95% CI)
578 (8,2 %)
HR (95% CI)
HR (95 % interval zaupanja)
HR (95% CI)
Razmerje ogroženosti (95 % IZ)
HR (95% CI)
Razmerje ogroženosti (95% IZ)
HR (95% CI)
RO (95-odstotni IZ)
HR (95% CI)
 RT (95 % IZ)
HR (95% CI) = 0.79 (0.66, 0.95)
2012: razmerje ogroženosti (95-% interval zaupanja) = 0,79 (0,66; 0,95).
HR (95% CI), p-value1
HR (95-% IZ), p
HR (95% CI): 0.77 (0.61, 0.97) p-value: 0.0257
Razmerje ogroženosti (95 % IZ): 0,77 (0,61; 0,97) p-vrednost: 0,0257
HR (95% CI); 1-sided p-valueb
HR (95 % IZ), 1-stranska p-vrednostb
HR (95% CI); 1-sided p-valuec
HR (95 % IZ); 1-stranska p-vrednostc
HR (95% CI)b
HR (95 % IZ)b
HR (95% CI)b p-valuec
HR (95 % CI)b vrednost pc
HR (99% CI)
RT (99-% IZ)
HR 0.16
[-8,2 %, 46,0 %]
HR 0.48
ROG 0,48
HR 0.53; p<0.0001
p < 0,0001
HR 0.55
ROG 0,55
HR 0.66
ROG 0,66
HR 0.68
ROG 0.68
HR 0.69
ROG 0,69
HR 0.70; p=0.0220
p = 0,0001
HR 0.74
ROG 0,74
HR 0.79
ROG 0,79
HR 0.81
Razmerje tveganja
HR 0.82
ROG 0,82
HR 0.83
ROG 1,02
HR 0.83; p=0.1882
tveganja 0,83; p = 0,1882
HR 0.86
ROG 0,86
HR 0.89
ROG 0,89
HR 0.90
ROG 0,90
HR 0.92
ROG 0,92
HR 1.00
ROG 1,00
HR 1.04
[0,94-1,64]
HR 1.10
ROG 1,10
HR 1.16
ROG 1,16
HR 1.18
ROG 1,18
HR 2.85
ROG 2,85
HR = 0.203 [95% CI: 0.150, 0.276]
Razmerje ogroženosti = 0,203 [95% IZ: 0,150; 0,276]
HR = 0.215 [95% CI: 0.146; 0.317]
razmerje ogroženosti = 0,215 [95% IZ: 0,146; 0,317]
HR = 0.43 [95% CI: 0.32, 0.58]
Razmerje ogroženosti = 0,43 [95% IZ: 0,32; 0,58]
HR = 0.46, 95%CI (0.31-0.69), p = 0.0001
HR = 0,46, 95 % IZ (0,31-0,69), p = 0,0001
HR = 0.57 [0.46, 0.71]
RT = 0,57 [0,46; 0,71]
HR = 0.628 [95% CI: 0.385, 1.024]
Razmerje ogroženosti = 0,628 [95% IZ: 0,385; 1,024]
HR = 0.75 (0.62, 0.90)b
HR = 0,75
HR = 0.79 (95% CI 0.53, 1.18)
HR = 0,79 (95-odstotni IZ 0,53, 1,18)
HR = 0.80 (95% CI: 0.66, 0.98), p = 0.029
HR = 0,80 (95 % interval zaupanja: 0,66; 0,98), p = 0,029
HR = hazard ratio;
HR (hazard ratio) = razmerje ogroženosti